What Does China's Price Manipulation Ruling On Unilever Mean For Global Pharma? (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The National Development and Reform Commission, China's state planning agency, charged consumer goods company Unilever a fine of RMB 2 million ($310,000) for price manipulation May 6. The NDRC action was taken in an effort to suppress consumer inflation, but a key takeaway, according to experts, is that multinational companies should be cautious about how they communicate pricing information to the market or they may find themselves in violation of China's Price Law, Anti-Monopoly Law or even foreign antitrust and anti-bribery rules